再生医療市場：製品別（幹細胞[自己由来、同種]、免疫療法、遺伝子療法、組織工学）、用途別（筋骨格系、癌、皮膚科、創傷治療、心血管疾患、眼疾患）-2028年までの世界予測

Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028

世界の再生医療市場は、2023年の160億米ドルから2028年には490億米ドルに達すると予測され、2023年から2028年の予測期間中の年平均成長率は25.1%である。新たな治療領域における広範な展望や、主要市場プレイヤー... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2024年1月26日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	293	306	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界の再生医療市場は、2023年の160億米ドルから2028年には490億米ドルに達すると予測され、2023年から2028年の予測期間中の年平均成長率は25.1%である。新たな治療領域における広範な展望や、主要市場プレイヤーによる共同研究や提携などの要因が、今後数年間で市場を押し上げると予測される。さらに、個別化医療への注目の高まりと再生医療規制認可の増加は、有利な市場成長をもたらすだろう。しかし、長期的なデータの欠如、倫理的・法的な懸念、治療費の高騰が市場を制限すると予測されている。
"再生医療市場では細胞治療分野が圧倒的シェアを占める"
製品に基づき、世界の再生医療市場は遺伝子治療、細胞治療（幹細胞治療[細胞移植、幹細胞治療製品｛自家療法、同種療法｝細胞ベースの免疫療法製品）、組織工学製品に区分される。幹細胞治療の人気の高まりが、細胞治療市場の拡大を牽引すると予想される。

"2022年の治療領域別では筋骨格系疾患分野が最大シェアを占める"
治療領域に基づき、再生医療市場は腫瘍学、筋骨格系障害、神経学、眼科、皮膚科＆創傷治療、心血管疾患、その他の用途に区分される。この背景には、整形外科疾患の罹患率の増加や筋骨格系の再生研究に対する関心の高まりがある。

「APAC地域はより速いペースで成長しそうである。
再生医療市場は、北米、欧州、アジア太平洋、中南米、中東、アフリカに区分される。APAC地域は予測期間中に大きなCAGRで成長すると予測されている。慢性疾患の高負担、一人当たり所得の増加、新技術に対する需要の高まりが、同地域の再生医療市場の成長を支えるものと期待されている。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側80％、需要側20
- 回答者の役職別（供給側）マネージャー - 45%、CXOおよびディレクター - 30%、エグゼクティブ - 25
- 地域別北米：55％、欧州：10％、アジア太平洋地域：20％、中南米：10％、MEA：5
レポート掲載企業リスト
- ノバルティスAG（スイス）
- バイオジェン社（米国）
- サレプタ・セラピューティクス社（米国）
- ギリアド・サイエンシズ社（米国）
- アムジェン社（米国）
- スミス・アンド・ネフュー（英国）
- 株式会社メディポスト（韓国韓国
- JCRファーマシューティカルズ株式会社（日本(武田薬品工業（日本）
- 武田薬品工業株式会社（日本）
- CORESTEM, Inc（韓国）
- ベリセル・コーポレーション（米国）
- MIMEDXグループ（米国）
- オルガノジェネシス社（米国）
- メドトロニック社（アイルランド）
- ブリストル・マイヤーズスクイブ・カンパニー（米国）
- オーソセル社（オーストラリア(オーストラリア）
- メソブラスト社（オーストラリア(オーストラリア）
- バイオレストラティブ・セラピューシーズ社（米国）
- Pluristem Therapeutics Inc.（米国）
- TEGOSCIENCE（韓国）
- 株式会社アンテローゲン（韓国韓国
- ブルーバードバイオ社（米国）
- Stempeutics Research Pvt Ltd. （インド(インド）
- シビオノ・ジーンテック Co.Ltd.（中国中国
- アスペクトバイオシステムズ(カナダ）
- Athersys, Inc.
調査範囲
この調査レポートは、再生医療市場の詳細な姿を提供しています。製品、治療分野、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主なメリット
本レポートは、再生医療市場全体とそのサブセグメントについて、最も近似した収益数値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのに役立ちます。本レポートは、利害関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（個別化医療への注目の高まり、再生医療における規制承認の急上昇、主要市場プレイヤーによる共同研究やパートナーシップの増加、新たな治療領域におけるスコープの拡大）、阻害要因（長期データの欠如、倫理的・法的懸念、治療費の高騰）、機会（人工知能やビッグデータとの統合、3Dプリンティングの可能性の活用、臓器移植件数の増加）、課題（様々な地域における有利な償還政策の欠如）の分析が、再生医療市場の成長に影響を与えています。
- 製品開発/イノベーション：再生医療市場で新たに発売された製品に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 本レポートは様々な地域の再生医療市場を分析しています。
- 市場の多様化：再生医療市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報。
- 競合評価：Novartis AG（スイス）、Biogen, Inc.（米国）、Sarepta Therapeutics, Inc.（米国）、Gilead Sciences, Inc.（米国）、Amgen Inc.（米国）、Smith+Nephew（英国）、MEDIPOST Co.(韓国)、JCRファーマシューティカルズ株式会社(日本)、武田薬品工業株式会社(日本)(日本）、武田薬品工業株式会社（日本）、CORESTEM, Inc（韓国）などが再生医療市場に参入している。

ページTOPに戻る

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.3 MARKET SCOPE 36
1.3.1 MARKETS COVERED 36
1.3.2 YEARS CONSIDERED 37
1.3.3 CURRENCY CONSIDERED 37
1.4 RESEARCH LIMITATIONS 37
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 38
1.7 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 1 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
FIGURE 2 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET 42
2.2 MARKET SIZE ESTIMATION 43
FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2022 43
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 44
FIGURE 5 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022 44
FIGURE 6 PRODUCT-BASED REVENUE ANALYSIS, 2022 46
2.2.1 PRIMARY INSIGHTS 47
FIGURE 7 VALIDATION FROM PRIMARY EXPERTS 47
2.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET 47
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 47
FIGURE 9 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET 48
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET 49
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 50
FIGURE 11 DATA TRIANGULATION METHODOLOGY 50
2.4 STUDY ASSUMPTIONS 51
2.5 RISK ANALYSIS 51
2.6 IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET 52
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH) 52
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 53
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 53
3 EXECUTIVE SUMMARY 54
FIGURE 12 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 54
FIGURE 13 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 55
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET 56
4 PREMIUM INSIGHTS 57
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW 57
FIGURE 15 FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH 57
4.2 NORTH AMERICA: REGENERATIVE MEDICINE MARKET 58
FIGURE 16 CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN REGENERATIVE MEDICINE MARKET 58
4.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 18 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
5.2.1 DRIVERS 61
5.2.1.1 Growing focus on personalized medicine 61
FIGURE 19 PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018–2022) 61
5.2.1.2 Emerging applications in new therapeutic areas 62
TABLE 4 REGENERATIVE MEDICINE MARKET: EMERGING APPLICATIONS 63
5.2.1.3 Increasing collaborations and partnerships by major market players 64
5.2.1.4 Increasing regulatory approvals in regenerative medicine 65
TABLE 5 LIST OF KEY PRODUCT APPROVALS IN REGENERATIVE MEDICINE MARKET, 2021–2023 65
5.2.2 RESTRAINTS 66
5.2.2.1 Lack of long-term data 66
5.2.2.2 Ethical and legal concerns and high cost of treatments 66
5.2.3 OPPORTUNITIES 67
5.2.3.1 Harnessing the potential of 3D printing 67
5.2.3.2 Integration with artificial intelligence and big data 68
5.2.3.3 Growing number of organ transplants 68
5.2.4 CHALLENGES 69
5.2.4.1 Lack of favorable reimbursement policies across various regions 69
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70
FIGURE 20 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES 71
5.4 PRICING ANALYSIS 71
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 71
TABLE 6 REGENERATIVE MEDICINE PRICE TREND 71
5.5 SUPPLY CHAIN ANALYSIS 72
FIGURE 21 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET 73
5.6 VALUE CHAIN ANALYSIS 73
FIGURE 22 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET 74
5.7 ECOSYSTEM ANALYSIS 74
FIGURE 23 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS 74
TABLE 7 ROLE IN ECOSYSTEM 74
5.8 TECHNOLOGY ANALYSIS 76
FIGURE 24 KEY STEPS IN GENE THERAPY 76
TABLE 8 STEM CELL THERAPIES AND GENE THERAPIES 76
5.9 PATENT ANALYSIS 78
TABLE 9 REGENERATIVE MEDICINE MARKET: INDICATIVE LIST OF PATENTS 79
5.10 KEY CONFERENCES & EVENTS IN 2024–2025 81
5.10.1 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025 81
TABLE 10 REGENERATIVE MEDICINE CONFERENCES IN 2024–2025 81
5.11 TARIFF & REGULATORY LANDSCAPE 82
5.11.1 FDA APPROVALS 82
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.12 PORTER’S FIVE FORCES ANALYSIS 87
TABLE 15 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 87
5.12.1 THREAT OF NEW ENTRANTS 87
5.12.2 THREAT OF SUBSTITUTES 87
5.12.3 BARGAINING POWER OF BUYERS 88
5.12.4 BARGAINING POWER OF SUPPLIERS 88
5.12.5 DEGREE OF COMPETITION 88
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 89
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 89
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS 89
5.13.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS 89
FIGURE 26 KEY BUYING CRITERIA FOR END USERS 89
5.14 PIPELINE ANALYSIS 90
TABLE 16 GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL 90
TABLE 17 CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL 93
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
TABLE 18 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 95
6.2 CELL THERAPY 95
TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 20 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 21 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 22 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 24 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.2.1 STEM CELL THERAPY 98
TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 99
TABLE 26 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 30 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.2.1.1 Cell transplantations 101
6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth 101
TABLE 31 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 32 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 33 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 34 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 35 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 104
6.2.1.2 Stem cell therapy products 104
TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 37 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 105
TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 39 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 40 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 41 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 107
6.2.1.2.1 Autologous therapy 107
6.2.1.2.1.1 Low risk of post-treatment complications to support segment growth 107
TABLE 42 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 46 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.2.1.2.2 Allogeneic therapy 110
6.2.1.2.2.1 High potential in disease treatment to ensure demand and development 110
TABLE 47 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 48 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 49 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 50 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 113
6.2.2 CELL-BASED IMMUNOTHERAPY 113
6.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth 113
TABLE 52 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 56 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 116
6.3 GENE THERAPY 116
6.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET 116
TABLE 57 APPROVED GENE THERAPIES, 2022 117
TABLE 58 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 59 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 60 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 61 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 62 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.4 TISSUE ENGINEERING 119
6.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET 119
TABLE 63 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 64 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 65 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 66 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 67 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 122
7 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA 123
7.1 INTRODUCTION 124
TABLE 68 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022 124
TABLE 69 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 125
7.2 ONCOLOGY 125
7.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET 125
TABLE 70 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS 126
TABLE 71 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 75 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 130
7.3 MUSCULOSKELETAL DISORDERS 130
7.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET 130
TABLE 76 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 77 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 78 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 79 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 80 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 133
7.4 DERMATOLOGY & WOUND CARE 133
7.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET 133
TABLE 81 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS 134
TABLE 82 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 84 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 85 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 86 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 136
7.5 CARDIOVASCULAR DISEASES 136
7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH 136
TABLE 87 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 88 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 89 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 90 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 91 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 139
7.6 OPHTHALMOLOGY 139
7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH 139
TABLE 92 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY 140
TABLE 93 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 94 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 96 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 97 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 143
7.7 NEUROLOGY 143
7.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH 143
TABLE 98 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 99 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 102 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 146
7.8 OTHER THERAPEUTIC AREAS 146
TABLE 103 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 147
TABLE 104 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 105 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 107 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 149
8 REGENERATIVE MEDICINE MARKET, BY REGION 150
8.1 INTRODUCTION 151
FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020–2022 151
TABLE 108 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022) 151
TABLE 109 REGENERATIVE MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION) 152
8.2 NORTH AMERICA 152
FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT 153
TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154
TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 113 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 114 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 115 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 155
8.2.1 US 156
8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market 156
TABLE 116 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 157
TABLE 117 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 118 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 119 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 120 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 159
8.2.2 CANADA 159
8.2.2.1 Rising government initiatives for regenerative medicine research to drive market 159
TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 160
TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 123 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 124 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 125 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 162
8.2.3 NORTH AMERICA: RECESSION IMPACT 162
8.3 EUROPE 163
TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 164
TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 129 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 130 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 131 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 165
8.3.1 GERMANY 166
8.3.1.1 Rising focus on clinical research and patent approvals to drive market 166
TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 166
TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 134 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 135 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 136 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 168
8.3.2 UK 168
8.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market 168
TABLE 137 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169
TABLE 138 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 139 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 140 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 141 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 171
8.3.3 FRANCE 171
8.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline 171
TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172
TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 144 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 145 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 146 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 173
8.3.4 ITALY 173
8.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market 173
TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 174
TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 149 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 150 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 151 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 176
8.3.5 SPAIN 176
8.3.5.1 Favorable regulatory environment to drive product pipeline 176
TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 177
TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 154 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 155 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 156 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 179
8.3.6 REST OF EUROPE 179
TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 180
TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 159 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 160 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 161 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 181
8.3.7 EUROPE: RECESSION IMPACT 182
8.4 ASIA PACIFIC 182
FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT 183
TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 184
TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 165 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 166 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 167 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 186
8.4.1 CHINA 186
8.4.1.1 Favorable government support for development of regenerative medicine to drive market 186
TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 187
TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 170 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 171 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 172 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 189
8.4.2 JAPAN 189
8.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies 189
TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 190
TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 175 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 176 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 177 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,
2021–2028 (USD MILLION) 192
8.4.3 INDIA 192
8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth 192
TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 193
TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 180 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 181 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 182 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 194
8.4.4 SOUTH KOREA 194
8.4.4.1 Strong research base and availability of funds to support market growth 194
TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 195
TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 185 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 186 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 187 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 197
8.4.5 AUSTRALIA 197
8.4.5.1 Increasing incidence of sports injuries to support market growth 197
TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 198
TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 190 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 191 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 192 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 199
8.4.6 REST OF ASIA PACIFIC 199
TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 200
TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 195 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 196 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 197 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 201
8.4.7 ASIA PACIFIC: RECESSION IMPACT 201
8.5 LATIN AMERICA 202
TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 203
TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 201 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 202 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 203 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 204
8.5.1 BRAZIL 204
8.5.1.1 Gradual increase in pharmaceutical R&D to support market growth 204
TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205
TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 206 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 207 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 208 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 206
8.5.2 REST OF LATIN AMERICA 206
TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 207
TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 211 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 212 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 213 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209
8.5.3 LATIN AMERICA: RECESSION IMPACT 209
8.6 MIDDLE EAST 210
8.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS 210
TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 210
TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 216 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 217 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 218 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 212
8.6.2 MIDDLE EAST: RECESSION IMPACT 212
8.7 AFRICA 213
8.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS 213
TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 213
TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 221 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,
BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 222 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 223 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 215
8.7.2 AFRICA: RECESSION IMPACT 215

ページTOPに戻る

Table of Contents

Summary

The global regenerative medicines market is projected to reach USD 49.0 Billion by 2028 from USD 16.0 Billion in 2023, at a CAGR of 25.1% during the forecast period of 2023 to 2028. Factors such as the wide scope in new therapeutic areas and collaborations and partnerships by major market players are predicted to uplift the market in the coming years. Additionally, rise in the focus of personalized medicine and rising regenerative medicine regulatory approvals will provide lucrative market growth. However, lack of long-term data and ethical and legal concerns and high cost of treatments are predicted to restrict the market.
“The cell therapy segment held the dominant share in the regenerative medicine market.”
Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The increasing popularity of stem therapy is expected to drive the expansion of the cell therapy market.

“Musculoskeletal disorders segment accounted for the largest share of the therapeutic area segment in 2022.”
Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and other applications. This can be attributed to the increasing preavalence of orthopedic disorders and growing interest on musculoskeletal regeneration research.

“APAC region is likely to grow at a faster pace.”
The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. APAC region is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support regenerative medicine market growth in the region.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80%, and Demand Side - 20%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -55%, Europe -10%, Asia-Pacific -20%, Latin America -10%, MEA- 5%
List of Companies Profiled in the Report:
• Novartis AG (Switzerland)
• Biogen, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Gilead Sciences, Inc. (US)
• Amgen Inc. (US)
• Smith+Nephew (UK)
• MEDIPOST Co., Ltd. (Korea)
• JCR Pharmaceuticals Co., Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• CORESTEM, Inc (South Korea)
• Vericel Corporation (US)
• MIMEDX Group, Inc. (US)
• Organogenesis Inc. (US)
• Medtronic (Ireland)
• Bristol-Myers Squibb Company (US)
• Orthocell Ltd. (Australia)
• Mesoblast Ltd. (Australia)
• BioRestorative Therapies, Inc. (US)
• Pluristem Therapeutics Inc. (US)
• TEGOSCIENCE (South Korea)
• ANTEROGEN.CO.,LTD. (South Korea)
• Bluebird bio, Inc. (US)
• Stempeutics Research Pvt Ltd. (India)
• Sibiono GeneTech Co. Ltd. (China)
• Aspect Biosystems Ltd. (Canada)
• Athersys, Inc. (US)
Research Coverage:
This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Growing focus on personalized medicine, steep rise of regulatory approvals in regenerative medicine, rising collaborations and partnerships by major market players, increasing scope in new therapeutic areas), restraints (Lack of long-term data, Ethical and legal concerns and high cost of treatments), opportunities (Integration with artificial intelligence and big data, Harnessing the potential of 3D printing, Growing number of organ transplants) and challenges (Lack of favorable reimbursement policies across various regions) are influencing the growth of regenerative medicine market.
• Product Development/Innovation: Detailed insights on newly launched products of the regenerative medicine market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan) and CORESTEM, Inc (South Korea) and among others in the regenerative medicine market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

再生医療市場：製品別（幹細胞[自己由来、同種]、免疫療法、遺伝子療法、組織工学）、用途別（筋骨格系、癌、皮膚科、創傷治療、心血管疾患、眼疾患）-2028年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?